Serological testing and treatment for plasmodium vivax malaria: A cluster-randomized trial in Ethiopia

dc.contributor.author	Ethiopian Food and Drug Authority
dc.date.accessioned	2026-02-24T10:41:14Z
dc.date.available	2026-02-24T10:41:14Z
dc.date.issued	2025
dc.identifier.uri	http://repository.iphce.org/xmlui/handle/123456789/5367
dc.description.abstract	The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for 60-90% of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.	en_US
dc.language.iso	en_US	en_US
dc.subject	Report	en_US
dc.title	Serological testing and treatment for plasmodium vivax malaria: A cluster-randomized trial in Ethiopia	en_US
dc.type	Report	en_US